Drugs / VRC-EBOADV018-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00374309 | Sep 2006 → May 2009 | Ebola hemorrhagic fever, surface antigen, glycoprotein 75 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-EBOADV018-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00374309 ↗ |
| Modality | Vaccine | “recombinant Ebola adenoviral vector vaccine” NCT00374309 ↗ |
| Route | Intramuscular | “Injections will be administered intramuscularly (IM) by needle and syringe.” NCT00374309 ↗ |